


Verinda Hobbs

## ABOUT FORCE



THESE EFFORTS ARE SUPPORTED
IN PART THROUGH A COOPERATIVE
AGREEMENT FROM
THE CENTERS FOR DISEASE
CONTROL AND PREVENTION
(NU58DP006677).



# 2024 Survey for People at High Risk for Breast / Gynecologic Cancers: ≤45 and Female, Nonbinary or Transgender Cohort

Total N=1261/Filtered N=328

Gene: 328 respondents

Gene	#	%
BRCA2	115	35%
BRCA1	97	30%
ATM	25	8%
CHEK2	23	7%
PALB2	22	7%
RAD51C	8	2%
TP53	3	1%
RAD51D	3	1%
RAD51D	14	1.1%
TP53	13	1.0%
BARD1	1	<1%
CDH1	1	<1%
PTEN	1	<1%
Multiple	13	4%

Age: 328 respondents

Age	#	%
18-25	14	4.3%
26-30	25	7.6%
31-35	57	17.4%
36-40	111	33.8%
41-45	121	36.9%

Breast cancer survivor or high risk (Previvor): 309

Survivor/Previvor	#	%
YBCS	47	15%
Previvor/High risk	262	85%

Gender: 328 respondents

Gender	#	%
Female	318	97.0%
Nonbinary, gender-fluid, gender nonconforming	10	3%
Prefer not to share	0	0%
Prefer to self- describe	0	0%

Transgender: 328 respondents

Transgender Y/N	#	%
Yes	6	1.8%
No	321	97.9%
Prefer not to share	1	0.30%

Race/ethnicity: 327 respondents

Race / Ethnicity	#	%
Non-Hispanic White	283	87%
Hispanic / Latine	21	6.4%
Black / African American	12	3.6%
Asian / Asian American	8	2.4%
American Indian / Alaskan Native	4	1.2%
Middle Eastern	4	1.2%
Hawaiian / Pacific Islander	0	0%

FORCE Survey on Needs of People at High Risk for Breast, Endometrial, Fallopian Tube or Ovarian Cancer Due to an Inherited Mutation or Family History. 2024. Unpublished.

©2021 Proprietary and Confidential. All Rights Reserved

# GENETIC TESTING RISK MANAGEMENT AND PREVIVORSHIP

"I still need peer support & financial support for previvors. Everything in funding is for cancer treatment, not prevention."



FORCE Survey on Needs of People at High Risk for Breast, Endometrial, Fallopian Tube or Ovarian Cancer Due to an Inherited Mutation or Family History. 2024. Unpublished.



#3

# Previvor

(prē-vīv'ər) n. 1. A survivor of a predisposition (or increased risk) for a disease such as cancer

Previvors and previvorship


TIME

20

# Guidelines for Breast Cancer Risk Management

## Breast cancer BRCA1/2 (female / AFAB)

- Breast awareness starting at age 18.
- Clinical breast exam, every 6–12 months, starting at age 25 years.
- Age 25–29 years, annual breast MRI screening with and without contrast
- Age 30–75 years, annual mammogram and breast MRI screening with and without contrast.
- Discuss benefits / risks / costs / limitations of risk-reducing mastectomy and risk-reducing medications.





NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, vs. 3 2024

## Guidelines Recommend Removal of Ovaries and Tubes



NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

# Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

Version 3.2024 — February 12, 2024

**NCCN.org** 

Continue

## Ovarian cancer BRCA1/2

- Recommend risk-reducing salpingo-oophorectomy (RRSO).
  - BRCA1: Between 35 40.
  - BRCA2: Given the later onset of cancer, it is reasonable to delay RRSO until age 40 - 45.

NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, vs. 3 2024

# Guidelines on Use of Hormones (HRT) after RRSO



- Hormone replacement therapy is generally <u>not</u> contraindicated and should be discussed with premenopausal patients without a personal history of breast cancer
- HRT recommendations should be tailored for the individual and should involve experts in menopause care.
- Premature menopause due to RRSO can be detrimental to bone, cardiovascular, sexual, psychosocial, and neurologic health and generalized quality-of-life. Hormones can reduce these risks.


# Barriers to Breast Screening

Q. How easy or difficult were the following aspects of your breast screening? 100% 90% 25% 80% 66% 54% 70% 67% 24% 60% 50% 40% 15% 23% 30% 11% 51% 20% 19% 23% 22% 10% 0% Finding a facility Finding a facility with Paying for breast **Emotionally preparing** responsive to your experience managing for screening or results screening high risk people needs 79 156 205 156 Easy Neutral 73 65 34 65 Hard 159 65 67 65




# Many Respondents Chose Risk-Reducing Mastectomy (RRM)

Q. Have you had, or are you in the process of scheduling a double mastectomy with or without reconstruction?



# Barriers to Risk-Reducing Mastectomy


Q. How easy or difficult were the following aspects of your risk-reducing mastectomy?





# Barriers to Risk-Reducing Mastectomy

Q. How easy or difficult were the following aspects of your risk-reducing mastectomy?





# Write In Comments on Barriers to Risk Management

## Themes:

- Financial burden
- Time and travel for expert care
- Access to fertility preservation
- Scanxiety
- Inconsistent or inaccurate information

The financial burden of MRIs and ultrasounds deters me from the additional screenings that are recommended.

I live in a services desert. Nearest breast MRI is 3.5 hr drive ONE WAY.

# Burden of Risk Management

The waiting game was excruciating. I cried for two days and didn't eat. I knew that having a double mastectomy was the ONLY thing that would bring me peace.

My surgery has not been scheduled, yet. We are not ready to close the door on another baby, but my insurance does not cover fertility treatments. The cost is about **\$15,000+.** The hardest part is knowing we want another baby, not being able to afford it, yet feeling like having one naturally would be a sort of death sentence for putting the surgery off for so long.

# Respondents Report Medical Advice Inconsistent with Guidelines

My daughter has a BRCA 2 mutation. Her doctors are telling her she will die if she doesn't have double mastectomy and oophorectomy immediately. She is 33 and in good health.


My provider was ordering regular annual screening mammograms until I sent her literature on screening recommendations for people with BRCA1 mutations.

# Breast Cancer Risk Management Research

Q. Has a doctor, nurse or other healthcare provider ever spoken to you about participating in a clinical trial related to hereditary breast cancer risk management?

Q. Are you interested in participating in hereditary breast cancer risk management clinical trials?

Q. Do you know how to find hereditary breast cancer risk management clinical trials?\*



<sup>\*</sup>Many of the respondents indicated that they knew about clinical trials because of FORCE.

# CAREGIVING AND FAMILY

"I provided care for my mother as she was dying of cancer as I was ending my own cancer treatment and learning about my BRCA2 options. Tough times."




FORCE Survey on Needs of People at High Risk for Breast, Endometrial, Fallopian Tube or Ovarian Cancer Due to an Inherited Mutation or Family History. 2024. Unpublished.


# Large Hereditary Cancer Caregiver Burden

#### Gap between resources needed and used

# 53% of respondents provided care to a relative with cancer

Q Have you ever provided support or care for a relative with cancer? N=328





# 120 Write-In Comments About Caregiving

### Themes:

- Generational trauma
- Caregiving for multiple relatives at the same time
- Going through personal diagnosis at same time as caring for a relative
- Gaps in information and support

A devastating experience losing my mom to cancer and a few months later losing my sister also to cancer. Most of it a daze.

I was a child 8-10 years old taking care of my grandmother taking turns with my siblings. I expect this is not uncommon and children caring for relatives rarely get support.

# FORCE PROGRAMS THAT ADDRESS NEEDS OF YOUNG SURVIVORS & PREVIVORS


"I really appreciate having this information readily available. It makes it easier to find relevant studies, without having to sort through the whole NIH website."



FORCE Survey on Needs of People at High Risk for Breast, Endometrial, Fallopian Tube or Ovarian Cancer Due to an Inherited Mutation or Family History. 2024. Unpublished.

# Expert Information on Hereditary Breast Cancer

- Many respondents
   received conflicting
   information about
   their medical options.
- We have treatment and riskmanagement guidelines and resources organized by cancer type and situation.



# Lobules Ducts Nipple Chest muscles Rib bone

anatomy of the breast

#### Stages

The stage of a cancer refers to whether the cancer has spread beyong Measuring the stage of breast cancer helps doctors decide how to can grow and spread:

#### cancer is very low, less than 1 percent. People with an <u>inherited mutation</u> in the genes listed below have a higher-than-average risk for breast cancer, often at a younger age. The risk varies based on multiple factors, including:

- aandar
- gender
- presence of a gene mutation
- personal and family history of cancer
- other risk factors

#### In the News



Study: Genetic testing among people wit cancer can find mutations that may affect treatment and prevention

## Is breast cancer hereditary? About 10 percent of people with breast cancer the risk for breast cancer and can cause cancer.

About 10 percent of people with breast cancer have an inherited mutation linked to increased cancer risk. Inherited mutations in the genes below increase the risk for breast cancer and can cause cancer to run in families. Some of these genes also increase the breast cancer risk in men and people assigned male at birth. Genetic counseling and testing can help people learn if they are at high risk.

Genes that Increase Breast Cancer Risk in Women and People Assigned

Genes that Increase Breast Cancer Risk in Men and People Assigned Male

ATM, BARD1 BRCA1, BRCA2, CDH1 CHEK2, NF1, PALB2, PTEN, RAD51C RAD51D STK11 TP53

BRCA1, BRCA2, CHEK2, PALB2

Other genes have been linked to an increase in breast cancer risk. Most of these are rare

Every person is at risk for breast cancer. The average lifetime risk for breast cancer in women is about 13 percent. This means that one out of every eight women will get breast cancer in their lifetime, usually after age 60. Men can get breast cancer, however, the average risk for male breast



# Individual Guidelines for Each High-Risk Gene

## Information for People with an Inherited PALB2 Mutation

#### What are the cancer risks for people with a PALB2 mutation?

People with an inherited mutation in PALB2 have increased risk for certain cancers, including:

- breast cancer (male and female)
- pancreatic
- fallopian tube
- ovarian

#### What can people with a PALB2 mutation do?

People with a PALB2 mutation have options for screening, prevention and treatment of hereditary cancer. There are expert quidelines and clinical trials that focus on:

- screening and early detection
- risk-reduction
- treatment

There may be other medical concerns for people with a PALB2 mutation, including a rare childhood disease known as Fanconi anemia which can happen in people who inherit a mutation in both copies of their PALB2 gene.

Each of these topics is outlined in more detail in the sections highlighted below.

#### In the News



Update: A breast cancer vaccine for people with an inherited BRCA1, BRCA2 or PALB2 mutation





Study: H. pylori bacteria infection a risk of stomach cancer in mutation carriers

#### Cancer Treatment for People with Inherited BRCA1 Mutations

Testing positive for an inherited BRCA1 mutation may affect your treatment options or eligibility for <u>clinical trials</u> studying which treatments work best. The following are examples of situations where a BRCA1 mutation may play a part in treatment decision-making. Note that when we use "men" and "women" we are referring to the sex you were assigned at birth.

Breast cancer

■ Pancreatic cancer

Ovarian cancer

■ Prostate cancer

#### **INFORMATION BY MUTATION TYPE:**

(Mutations in alphabetical order)









. . . . . .







#### Breast Cancer

#### Surgical decisions

Because of the very high risk for a second (or third) breast cancer diagnosis, women who are diagnosed with breast cancer who test positive for an inherited mutation in BRCA1 often choose <u>bilateral mastectomy</u> rather than lumpectomy and radiation. Mutation carriers who undergo mastectomy are less likely to develop a second breast cancer.

Unlike women, the risk for a second breast cancer diagnosis in men with a BRCA1 mutation is low. For this reason, bilateral mastectomy may not be recommended.

#### Treatment options for metastatic breast cancer

The PARP inhibitors, Lynparza (also known as olaparib) and Talzenna (also known as talazoparib) both have received FDA approval for treating metastatic breast cancer caused by a BRCA mutation.

#### Treatment options for early-stage, high-risk breast cancer

The PARP inhibitor, Lynparza is FDA approved to treat people with early-stage, HER2-negative breast cancer who have an inherited BRCA mutation and who are at high risk for recurrence.

#### In the News



Topic : Progress in the treatment of triple-negative breast cancer

# Information on High Priority Topics

- 67% needed information about early-onset menopause
- 44% found it hard to make decisions about breast reconstruction

#### Managing Menopause with Hormones

You should talk with your health care provider who can help you make a decision about whether hormone replacement is right for you. Note that when we use "women" we are referring to people assigned female at birth

#### Benefits and risks of hormone replacement therapy

The decision to take hormone replacement after menopause is a very personal decision. There are benefits and risks for hormone replacement that depend on your personal situation. Hormone replacement can improve many of the symptoms and side effects of menopause, including:

- osteopenia and osteoporosis
- vaginal side effects

However, hormone replacement has risks, including

- Oral estrogen has been linked to an increased risk for blood clots and stroke. Estrogen skin
- When estrogen is combined with systemic progesterone it can lead to an increased risk of breast
- When estrogen is used without progesterone, there is an increased risk for uterine cancer.

\*Note: much of the research on these risks studied older women who took hormone replacement

- For healthy, high risk previvors (women who never had a cancer diagnosis) who ovaries before age 45, most experts believe the benefits or hormone replacemen
- For people who have been diagnosed with breast cancer, most experts believe hormone replacement outweigh the benefits.

Once you have made a decision to take hormone replacement, there are additional type of replacement, including

the type of hormones contained in the preparation

#### Reconstruction > Tissue Transfer

#### About my surgery

Bilateral prophylactic nipple-sparing maste

#### Photos

Click an image below to view a larger image



#### Find a Menopause Expert



#### **Pregnancy After a Cancer Diagnosis**

Research suggests that it is safe for many cancer survivors to become pregnant after treatment. However, the exact risks for pregnancy in cancer survivors vary depending on the woman's health, the type of cancer she had, and the treatment she received. For women diagnosed with breast cancer, pregnancy has not been linked to an increase the risk of recurrence for most survivors. Further, breast cancer treatment does not appear to affect the long term health of children conceived after treatment

There are several topics that women considering pregnancy after treatment should discuss with her health care provider before becoming pregnant, including:

- when it is safe to become pregnant
- any medical issues caused by cancer or treatment that may affect her pregnancy
- risk for cancer recurrence
- risk for a second cancer diagnosis and recommendations for managing this risk

#### In the News




Study: Pausing hormone therapy to pursue pregnancy does not increase the shortterm risk of early-stage cancer recurrence

Women who paused hormone therapy treatment of early-stage hormone receptorpositive (HR-positive) breast cancer to



# eXamining the Relevance of Articles for You (XRAY)

FORCE's XRAY Program helps people look behind the headlines by providing plain language summaries of relevant research.



## Curated Resources for Previvors



#### What is a Cancer Previvor?

The meaning of the word "previvor" is a "survivor of a predisposition to cancer." Previvors are people living with an inherited mutation who have never been diagnosed with cancer.

The term includes people with an inherited mutation, a family history of cancer, or some other factor that increases their risk for cancer.

Previvors have medical options to manage their cancer risks. These include:

- enhanced screening to find cancer early and at its most treatable stage.
   medications, lifestyle changes and other approaches to lowering cancer
- medications, lifestyle changes and other approaches to lowering cancerisk.
- surgery to remove organs at high risk before cancer develops.
- clinical research studies that are testing new ways to manage risk.

#### Genes linked to hereditary cancer risk

Check out our list of genes to learn more about the risks and recommendations for previvors in each selected gene.

Information by gene

Cancer risks and management guidelines vary by gene, therefore, it's important to know which mutation you have. A genetics expert can help you understand more about your

#### What's behind the definition of previvor?

FORCE coined the term in 2000 in response to a challenge by a FORCE member who posted, "I need a label!"

Prior to our coining the term, the medical community referred to previvors as 'unaffected carriers,' a designation many people found dismissive. The term previvor unites a community of important stakeholders to advocate for more research resources and policy protections.







**Young Previvors Support Group** 



Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention Study)

#### Clinicaltrials.gov identifier:

NCT04711109

#### Prevention

Prevention study enrolling women ages 25-55 with a BRCA1 mutation


More info

# Emotional Support from Peers

- 77% found it hard to emotionally prepare for mastectomy.
- 66% found it hard to emotionally recover from mastectomy.
- 67% found it hard to emotionally prepare for oophorectomy surgery (RRSO).
- 51% found it hard to emotionally recover from RRSO surgery.








# 1-on-1 Navigation from Peers

# Many respondents needed navigation assistance:

- 55% needed help related to genetic testing.
- 54% needed help related to caregiving.
- 49% needed help related to breast cancer risk management.
- 47% needed help related to gynecologic cancer risk management.

#### Get Matched for 1:1 Support

Our free Peer Navigation Program connects cancer survivors, people at high risk and their caregivers to support and resources personalized for their situation. This program is for individuals who have just learned about their hereditary cancer risk as well as those who have known about it for many years.



# Navigation to Healthcare Expertise and Services


- 40% of respondents found it hard to find a facility that offers fertility preservation.
- 22% of respondents found it hard to find a facility with expertise in managing high-risk patients.



https://bit.ly/force-find-experts

# Our Community is Interested in Participating in Research

- 88% are interested in participating in clinical trials.
- 88% have never been told about studies by their healthcare team.
- 59% do not know how to find a study relevant to their situation.





Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

#### Clinicaltrials.gov identifier:

NCT05932862

#### Treatment

Treatment study for people with advanced solid tumors



Social Support and Coping Strategies Among LGBTQIA+ Cancer Patients

#### Surveys, Registries, Interviews

This study explores how different levels of support systems influence coping strategies among LGBTQIA+ cancer patients



PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

#### Clinicaltrials.gov identifier:

NCT04995198

More info

#### Surveys, Registries, Interviews

A screening registry for people diagnosed with prostate cancer **BRCA-P** 

#### **BRCA1** Breast Cancer **Prevention Study**

Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention

#### Clinicaltrials.gov identifier:

NCT04711109

#### Prevention

Prevention study enrolling women ages 25-55 with a BRCA1 mutation

More info

More info



https://bit.ly/force-research

## Research Search and Enroll Tool

Custom database of studies enrolling people with inherited mutations.

- Study listings written in plain language
- Includes studies on:
  - Treatment
  - Detection, prevention, interception, risk
  - Quality of life
  - Surveys and registries

Printer Friendly Page 🖶



Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention Study)

#### Clinicaltrials.gov identifier:

NCT04711109

#### Prevention

Prevention study enrolling women ages 25-55 with a BRCA1 mutation

#### Study Contact Information:

For additional information, please contact:: Judy E. Garber, MD, MPH: (617) 632-5961 or by email: judy\_qarber@dfci.harvard.edu

#### THIS STUDY IS OPEN TO:

You may be eligible to participate in the BRCA-P Study if you:

- Are a woman who has a confirmed BRCA1 gene mutation (variant)
- Are 25 to 55 years old Do NOT have a history of breast or ovarian cancer
- Are not pregnant or breastfeeding
- Have not had a mastectomy (removal of breast(s) by surgery)

We encourage women of all racial and ethnic groups to participate in this study so that it fully represents all populations affected by BRCA1 mutations

#### Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention Study)

#### About the Study

The BRCA-P Study is an international research study for women who are born with a mutation (change) in one of their BRCA1 genes. The main purpose is to find out if the study medication, denosumab, can decrease the risk of developing breast cancer compared to a placebo (inactive substance) in women with a BRCA1 gene mutation.

Denosumab is a drug approved by the FDA for treating osteoporosis (weakening of the bones) in healthy people. It is also approved for serious bone problems in people who have cancer that has metastasized (spread) to the bone. Some common side effects of denosumab include muscle and bone pain, shortness of breath, and low levels of calcium and phosphate in the blood. If you choose to take part in this study, your study doctor will carefully decide if denosumab is right for you.

Type of Study:

#### THIS STUDY IS NOT OPEN TO:

The study is not open to people assigned at birth as male.


The study is not open to women:

- who have had a prior bilateral mastectomy.
- who have a history of breast or ovarian cancer (including fallopian and peritoneal cancer).

# State Laws on Insurance Coverage for Breast Screenings

Information about state laws related to insurance coverage for care.


 23% of respondents had difficulty paying for guidelinerecommended breast screening.



# Appeal Letters and Financial Resources

Providing sample appeal letters and links to programs and partners that offer financial assistance.

- 54% of respondents needed financial support.
- 73% of respondents found it hard to pay for fertility preservation.



# Partnership Program

Working with partners to increase access to information, inclusive care and resources.

Through our partnership program, we work together with other organizations to advocate for greater awareness, broader access to care, and better treatment and prevention options for all those who are impacted by hereditary cancer

- You can view or search for partners below.
- If you are interested in becoming a partner, you can read more about our program and apply here.

#### Find a Partner

Search for a Partner by Areas of Focus (Multiple checkboxes allowed.)

O AND - O OR

And = Both (or more) of your selections must be relevant to this partner. This will narrow your

Or = Any of your selections must be relevant to this partner. This will provide number of results

- □ Breast cancer
- ☐ Gastrointestinal cancer (colorectal, gastric. pancreatic)
- ☐ Gynecologic cancer (endometrial, fallopian tube, ovarian)
- □ Melanoma
- ☐ Urogenital cancer (bladder, kidney, prostate)
- □ Other cancers
- ☐ Hereditary cancer

- ☐ Race, ethnicity, sexual ☐ Financial support or na
- □ Genetics
- □ Behavioral health or w
- □ Clinical services □ Research
- ☐ Health Equity
- □ All Cancers

- Foundation
- ► CCARE Lynch Syndrome



- ▶ ABCD: After Breast Cancer Diagnosis
- ▶ Academy of Oncology Nurse and Patient
- ▶ AIM at Melanoma
- ▶ AliveAndKickn
- ▶ AnCan
- ► Bag It
- ▶ Basser Center for BRCA
- ▶ Bay Area Cancer Connections
- ▶ Black Health Matters
- ▶ Bloom Syndrome Association
- ▶ Breast Cancer Resource Center
- ▶ Breast Cancer Support Services of Berks
- ▶ Breastcancer.org
- ▶ BreastReconstruction.org
- ▶ Byrd Cancer Education and Advocacy
- ► Cancer Support Community
- ► Cierra Sisters
- ▶ Colon Cancer Coalition

- ▶ GI Cancers Alliance
- ▶ HIS Breast Cancer Awareness
- ▶ Hope for Stomach Cancer
- ► Hospital Oncológico Dr. Isaac González Martinez
- ► Hospitales HIMA•San Pablo
- ▶ JScreen

PARTNER SPOTLIGHT

- ▶ Keepers of the Flame Foundation, Inc.
- ▶ Know Your Lemons Foundation
- ▶ Let's Win Pancreatic Cancer
- ▶ Living Beyond Breast Cancer
- ▶ Male Breast Cancer Global Alliance
- ► Male Breast Cancer Happens
- ▶ Malecare
- ► Mayberry Memorial
- ▶ Metastatic Breast Cancer Alliance
- ► Metavivor Research and Support, Inc.
- ▶ National Alliance for Hispanic Health
- ▶ National Association of Chronic Disease Directors
- ▶ National Coalition for Cancer Survivorship
- ▶ National LGBT Cancer Network

- ▶ Patient Advocate Foundation
- ▶ Patient Empowerment Network (PEN)
- ▶ Pink Fund
- ▶ Pink Ribbon Moms
- ▶ Prevent Cancer Foundation
- ▶ Proiect Life
- ▶ Prostate Conditions Education Council
- ▶ PTEN Hamartoma Tumor Syndrome Foundation
- ► SHARE Cancer Support
- ▶ Sharsheret: The Jewish Breast & Ovarian Cancer Community
- ▶ Surviving Breast Cancer
- ► Susan G. Komen
- ▶ The Beautiful Gate Cancer Support and Resource Center
- ▶ The Chrysalis Initiative
- ▶ The Clearity Foundation
- ▶ The Missing Pink Breast Cancer Alliance
- ▶ The Raymond Foundation
- ▶ Tigerlily Foundation
- ▶ Touch, The Black Breast Cancer Alliance

# Partners Share Syndicated Content

Partners help disseminate XRAY articles and research studies using syndicated content.



ABOUT TOUCH > #BLACKDATAMATTERS BLESSTIE LOVE YOUNG WOMEN NEWS > RESOURCES >



Women diagnosed with breast cancer between the ages of 15-

Young, Empowered & Strong: Web-Based Symptom Monitoring and Self-Management for Young Adult **Breast Cancer Survivors (YES Study)** 

The goal of this study is to measure whether a web-based patient-reported symptom monitoring and self management portal, Young, Empowered & Strong (YES), improves the quality of life of young breast cancer survivors.

Read More...



Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas



anti-cancer di tolerance, ho Read More...



Genes, asesoría genética y desigualdades en el cáncer de endometrio

HOME ABOUT SERVICES RESEARCH CONTACT

Los casos de cáncer de endometrio están en aumento y es un tipo de cáncer hereditario. La asesoría genética tiene ventajas tanto para las personas con cáncer como para sus familiares. Sin embargo, las mujeres negras con cáncer de endometrio, por lo general, presentan resultados peores que las mujeres blancas. Las mujeres negras con cáncer de endometrio que dan positivo para una mutación hereditaria tienen menos probabilidades de poder consultar a un asesor genético. Es por estas desigualdades que las mujeres negras se beneficiarían al tener un mejor acceso y ser canalizadas con especialistas en asesoría genética. (Publicado el 14/12/23)



#### La inmunoterapia mejora los resultados del tratamiento contra el cáncer de endometrio avanzado

El programa eXamining the Relevance of Articles for You (Examinar la relevancia de artículos para usted o XRAY, por sus siglas en

El tratamiento estándar contra el cáncer de endometrio avanzado puede cambiar en un futuro cercano. En un estudio se descubrió que las personas con cáncer de endometrio avanzado o recurrente que recibieron inmunoterapia con quimioterapia presentaron meiores resultados que las personas que sólo recibieron quimioterapia. (Publicado el 4/12/23)

## Partner Collaborations

Working with partners to increase access to information, inclusive care and resources.

August 12, 2024

#### WHY GENDER MATTERS IN BREAST CANCER CARE

A new survey of healthcare providers, policy, and advocacy organizations conducted by <u>FORCE</u> and <u>Living Beyond Breast Cancer</u> in partnership with the <u>National LGBT+ Cancer Network</u> identified improving gender and sexual orientation inclusivity as a priority in providing competent care.

Every patient should have high-quality health care that meets their needs. Many health issues are related to gender or are impacted by gender—everything from cancer screenings, drug prescriptions, and health recommendations for diet or heart health to the impact of hormonal status on treatment plans (<u>1-8</u>).



in partnership with: lgbtqi+ cancer network

Clear communication between patient and provider is needed to ensure appropriate care. Healthcare is best when patients can effectively talk and be heard by their provider and feel safe disclosing relevant details that may impact their situation (9-11). Unfortunately, we know that many people, especially LGBTQIA+ people, don't have access to high-quality care or feel safe disclosing relevant details with their providers (12-14). Guidance for providers on best

https://bit.ly/force-gender-matters

## Partner Collaborations

Working with partners to increase access to information, inclusive care and resources.

# WHAT YOUR GRANDPARENTS DIDN'T KNOW ABOUT CANCER COULD SAVE YOUR LIFE!

Do you know your family health history? Does your family t the topic? Let's break the cycle of silence! Join FORCE and about cancer genetics and how this information could prot






#### Wednesday, September 18 at 9:00 PM ET

Join FORCE and the National Pan-Hellenic Council for a free lifesaving workshop!

Register now: bit.ly/nphc-force-workshop









Verinda Hobbs
FORCE Partnership Strategy
Manager
Cancer Previous



Angela Trepanier, CGC

Genetic Counselor

Wayne State School of Medici



Wenora Johnson
FORCE Board President
Colorectal and Endometrial
Cancer Survivor



Junius Nottingham, Jr.
CEO of J-NOTT-GTT Corp.
Colorectal Cancer Survivor
FORCE Volunteer

https://bit.ly/npch-force-workshop

# Stay in Touch!

Website: FacingOurRisk.org

Helpline: 866-288-RISK

**Email:** info@FacingOurRisk.org

Get Social: FacingOurRisk

